



23 May 2024

Company Announcements Office
Australian Securities Exchange

Appointment of Interim Chief Technology Officer

Further to Vectus Biosystems Limited's (Vectus or the Company (ASX:VBS)) announcement to the market on 20 May 2024, the Company advises the appointment of an interim Chief Technology Officer, Dr Ivan Rajkovic. Dr Rajkovic's profile is set out below. He was instrumental in the development of the entire intellectual property (IP) portfolio of Vectus, as a recognised IP expert, from the inception of the Company.

In conjunction with this appointment, Vectus is in the process of assembling a team of additional experts, both in science and commercialisation, to support the expansion of the Company's outreach to pharmaceutical companies globally. Vectus anticipates being in a position to add the data from its Phase Ib clinical trials in relation to the Company's lead compound VB0004, in the near term.

Dr Ivan Rajkovic has been associated with Vectus since 2005, working closely with Dr Karen Duggan on developing an IP strategy for the Company, patent drafting and prosecution, and patent portfolio management.

Dr Rajkovic has over 17 years experience in biomedical research, in both academic and commercial settings. His career comprised over 13 years post-doctoral academic research, and a further four years of commercial research and development, in the field of genetic engineering and bio-pharmaceuticals. Dr Rajkovic's particular technical expertise lies in the areas of molecular immunology and oncology, biomolecular engineering, transgenics, gene therapy, microbial biochemistry, diagnostics and pharmaceuticals. He is an author of 45 publications in peer-reviewed scientific journals and books in the fields of molecular and cellular biology and immunology.

Dr Rajkovic was a partner in a major Sydney-based IP firm for 14 years. Since his retirement from the partnership, Dr Rajkovic has been advising a number of companies in the life sciences field on patent portfolio structuring, patent filing strategies and portfolio management.

Vectus Biosystems Limited

Dr Ron Shnier
Chairman

This announcement was authorised by the Company's Board of Directors.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

Level 3, 11 Julius Avenue, North Ryde, NSW 2113 Australia Telephone: +61 2 8876 8200 Facsimile: +61 2 9662 1720
Email: info@vectusbiosystems.com.au
Website: www.vectusbiosystems.com.au